Clinical Trial Update: ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ASTX727 with donor lymphocyte infusions after allogeneic stem cell transplantation in very high risk myelodysplastic syndromes or acute…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• ASTX727 (cedazuridine/decitabine)
• Donor Lymphocyte Infusions

Snippet

Sponsor: Groupe Francophone des Myelodysplasies | Conditions: MDS, AML | Phase 2 | Status: COMPLETED